Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent

Please subscribe to IBJ to decode this article.

nf rddootltarc1ep madee me rpsii Cei eelcci7hatruheF h. em nacit,atrtm hpaac t atLn asafl g gldLnfnnp Ectytmg- omweainrelutrevtwuS da o;oarnion hosrt u # cdroyh byyg8ss t h,ewoys&ne3fnn da itdactanroctu2eoarripig er ih b.ldnuianper

ahon .ms dmsdw ruai;av ip pbon;eahils2aiatckttantaiolufae shrn on rtsdod adoawt is8icbemnlicltniirdarnbuoeoounxm e ,Igt tbanuscerkvandcLnind,&alos onkr aed nwn ig -t1mneuuai wgmdtht&tptrgooano1#na r sooi r gsmabe oo Tf isd ldeapefoxvatnt2t-drcdiniatd seo sho sc aemuo os2esvd,#2erm 8

tedg1sde fot mdaos nha2;aiscttn ngs.s0 rr2tsurdi piipogl ar i m utli8etsraeeoninra nvdttetpaoospoii weotw ottnt2r8m&s&eolu#issLosyh duu fturLnts2t annfiahp ;iat#i i

cs 1 hlr troilrft iecsitolnri. im-i,Si ooaa, m cy nLtfnearanna. hnerlele ea$eaigpoh cn3o9.gdscT-aa tradniehf a roep f yanrao,t 3 e rlrsgn ta e f0t7e .il ofcus1tcet-bu homsnt3p irnxri$ i 0rltt gho$ o6rx nre u 0igaped tmxetiameh nq

yae &bs nm1uacar stoatLtndnnmiaft10a e cpgseespoayn e a9aiosl g rI eio 17nh.na ylhnceuvoiethldn,t i8-nr#upssc ehf2 ixt it e oa etac dw;2di7l

b. s s"ununp/essho hifcwutonFaemeco90c 6oe nowed0odnmon la r-# -frporaub7Tloartteaabnlapatp rD a>>r ajrvti-regt ess rrhneatFalolno/ao,antycnliae2naro_//

u6cdldatt os.a midgaliunhnda 0eh r iysuev e glts$ahlnlsmtpaaey0s na olltt us cAr nuinlei eaupdchr n

fttreL r i Oevvdavl2s#dtiiL yerasisodiai i v2i,etnp h iuainc cdns ;new;pdrAihd8n0o&nauy2urp nlthrrsy8ea2luno,teee&al osL ayotvs sdosddWtglprehtoousnfcd f t iprlaaai msoitmsw .odsi1 t #patent

emStdseaessgunwra.pdo 0p,rtaaSooeme in1 1o 5eipf0ded oot0n 5 et ndaeed.liowUtae t eos2e0iierait otnsifi aee sef Tn2aet ratidStdhtradastleenI mthi, nsfoutclc n ds s d0p, d i0Sglh a0ih

0&1 #;6